N@N

MEMPHIS--([ BUSINESS WIRE ])--MRI Interventions (OTCBB: MRIC) CEO, Kimble Jenkins, has released the following letter to stockholders:

Dear Fellow Stockholders:

I am pleased to report to you several significant, positive developments at MRI Interventions.

We are cleared for trading - MRI Interventions will begin trading as a public company on Monday, under the symbol aMRICa. This achievement is the result of many months of work, including extensive regulatory filings with the Securities and Exchange Commission and a detailed review process conducted by the Financial Industry Regulatory Authority.

We made the cover - Our ClearPoint Neuro Intervention System reached a significant milestone in March, being featured on the cover of the Journal of Operative Neurosurgery. As a leading peer-reviewed journal for neurosurgeons, we are very pleased with this recognition. You can access an abstract of the journal article by clicking on the following link: [ http://journals.lww.com/neurosurgery/toc/2012/03001 ]

Installations are growing - ClearPoint systems are installed at a growing number of hospitals, including many of the leading neurosurgical centers in the country. ClearPoint sites include UCSF Medical Center, Emory Healthcare, Memorial Sloan Kettering Cancer Center, the National Institutes of Health, Henry Ford Health Systems, MD Anderson, University of Pittsburg Medical Center, and University of Wisconsin among others. We are making progress outside the US as well. At the end of last year, we completed our first installation in Europe and expect to open additional ClearPoint sites in Europe over the coming quarters.

We are making a difference- ClearPoint neuro procedures are continuing to go very well. Neurosurgeons have now used the ClearPoint system as the minimally invasive neurosurgical platform in their treatment of patients suffering from a range of neuro diseases including Parkinsonas disease, Dystonia, Pediatric Dystonia, Brain tumors, Epilepsy and Touretteas syndrome. We are gratified to have an opportunity to benefit a growing number of patients.

For a more detailed overview of the Company, I invite you to review our Investor Presentation, which can be found at the following link: [ http://ir.stockpr.com/mriinterventions/presentations ]. Also, if you havenat had a chance to see a demonstration of our ClearPoint system, please go to: [ http://www.mriinterventions.com/clearpoint/demonstration-video ].

As we begin this exciting new chapter in the life of the company, I again want to thank our stockholders for their trust and confidence. With your support, we look forward to continuing our efforts to change peopleas lives with our innovative products and technologies.

Very truly yours,

Kimble L. Jenkins
Chief Executive Officer

About MRI Interventions, Inc.

Founded in 1998, MRI Interventions, Inc. is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospitalas existing MRI suite, the companyas FDA-cleared ClearPoint system is designed to enable a range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTracea" system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the companyas interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit [ www.MRIinterventions.com ].

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.Forward-looking statements often can be identified by words such as aanticipates,a abelieves,a acould,a aestimates,a aexpects,a aintends,a amay,a aplans,a apotential,a apredicts,a aprojects,a ashould,a awill,a awould,a or the negative of these words or other words of similar meaning.Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk.Uncertainties and risks may cause MRI Interventionsa actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventionsa forward-looking statements.For MRI Interventions, particular uncertainties and risks include, among others:demand and market acceptance of its products; its ability to successfully complete the development of, and to obtain regulatory clearance or approval for, future products, including its current product candidates; availability of third party reimbursement; the sufficiency of its cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; its ability to protect and enforce its intellectual property rights; its dependence on collaboration partners; the retention of its sales representatives and independent distributor; the impact of competitive products and pricing; and the impact of the commercial and credit environment on it and its customers and suppliers.More detailed information on these and additional factors that could affect MRI Interventionsa actual results are described in MRI Interventionsa filings with the Securities and Exchange Commission, including, without limitation, the quarterly report on Form 10-Q for the quarterly period ended March 31, 2012.Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in MRI Interventionsa expectations or any change in events, conditions or circumstances on which any such statements are based.